Home>Topics>Companies>Johnson & Johnson

Johnson & Johnson JNJ

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. Should I Invest In AT&T And Verizon For Their High Dividend Yields?

      Headlines

      Mon, 28 Jul 2014

      By Dividend Growth Investor : Most readers are probably aware that it has been getting more difficult to find decent values in the current environment. When I ran my screens for valuation, I stumbled upon AT&T (NYSE: T ) and Verizon (NYSE: VZ ), which are telecom behemoths in the US. AT&T has ...

    2. Imbruvica expands label

      Headlines

      Mon, 28 Jul 2014

      The FDA approves a label expansion for Janssen Biotech's ( JNJ -0.2% ) Imbruvica ( ibrutinib ) to include patients with chronic lymphocytic leukemia (CLL) who carry a 17p deletion , a

    3. Why Merck Is Heading To $65

      Headlines

      Mon, 28 Jul 2014

      By Wall Street Playbook : With better-than-expected results coming in from AbbVie (NYSE: ABBV ), Johnson & Johnson ( NYSE : JNJ ) and other dominant names in Big Pharma, Merck (NYSE: MRK ) investors have raised the bar. They are demanding

    4. CHMP's positive on Imbruvica for blood cancer

      Headlines

      Fri, 25 Jul 2014

      deletion or TP53 mutation who are unsuitable for chemo-immunotherapy. Ibrutinib is being co-developed by Johnson & Johnson ( JNJ -0.2% ) unit Janssen-Cilag International NV and Pharmacyclics Switzerland GmbH. Once approved, Janssen

    5. Europe backs new leukaemia drugs from J & J and Gilead

      Headlines

      Fri, 25 Jul 2014

      LONDON, July 25 (Reuters) - Two new leukaemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a...

    6. JNJ : Another Win Added To The Earnings Season

      Headlines

      Thu, 24 Jul 2014

      Balanced Investing : Bringing Sandra Peterson to turnaround the failing McNeil Consumer Healthcare division of Johnson & Johnson ( NYSE : JNJ ) has proven quite fruitful for the company. Although her strategic moves may have sounded abrupt at the beginning

    7. Organovo signs drug discovery agreement with J & J unit

      Headlines

      Thu, 24 Jul 2014

      Organovo (NYSEMKT: ONVO ) are up 17% premarket on robust volume in response the signing of a research agreement with Johnson & Johnson unit Janssen Research and Development to evaluate the use of 3D bio-printed tissue in drug discovery. Financial

    8. Zimmer Sees Anemic Domestic Demand Offset by Stronger International Markets in 2Q

      Commentary

      Thu, 24 Jul 2014

      in our valuation. With quarterly revenue growth of 1% in constant currency, Zimmer trailed rivals Stryker and Johnson & Johnson 's DePuy business. In recent quarters, Zimmer has benefited from the introduction of its new Persona knee. However

    9. Building my 'Income Builder' Portfolio / Good bye JNJ - hello GSK

      Commentary

      Wed, 23 Jul 2014

      Balanced funds thread examined income builder funds and specifically Thornburg Income Builder. I'll let that rest. I sold JNJ recently when it topped 100 - had a great gain - love the company and the industry - but don't like the ~2.7 yield

    10. HIV combo therapy candidate fails Phase 3

      Headlines

      Tue, 22 Jul 2014

      a Phase 3 trial comparing a once-daily dose of Solzentry ( maraviroc ) ( PFE +0.7% ) with Prezista (darunavir) ( JNJ +1.1% ) and Norvir (ritonavir) ( ABBV +0.2% ) to emtricitabine / tenofir with darunavir plus ritonavir (DRV

    « Prev12345Next »
    Content Partners